Condition: Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) · Sponsor: Centre Hospitalier Universitaire Dijon
This study is a two periods multi-center Phase II trial, with a 6 months double-blind, placebo-controlled period followed by open label period, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polymicrogyria syndrome (MCAP)
This description comes directly from the study's public registry record.
Laurence OLIVIER-FAIVRE · 0380295313 · laurence.faivre@chu-dijon.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens | Amiens, France | Recruiting |
| CHU d'Angers | Angers, France | Recruiting |
| CHRU Brest | Brest, France | Not Yet Recruiting |
| HCL - Groupement Hospitalier Est Hôpital Femme-Mère-Enfant | Bron, France | Recruiting |
| Chu Estaing | Clermont-Ferrand, France | Recruiting |
| Chu Dijon Bourgogne | Dijon, France | Recruiting |
| CHU Dijon Bourgogne - CIC-P | Dijon, France | Active Not Recruiting |
| CHU de Lille | Lille, France | Recruiting |
| CHRU Nîmes | Nîmes, France | Recruiting |
| AP-HP Hôpital Necker-Enfants Malades - CIC | Paris, France | Active Not Recruiting |
| AP-HP Hôpital Necker-Enfants Malades | Paris, France | Recruiting |
| CHU Rennes | Rennes, France | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05577754